Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Healthy Volunteer
Researchers are studying the effectiveness, safety, and tolerability of a vaccine against Clostridioides difficile C. difficile infection in adults aged 65 years and older. The study aims to reduce the number of C. difficile infections, a serious cause of diarrhea, by comparing the vaccine to a placebo. This is a phase 3, randomized, double-blinded trial sponsored by Pfizer. Participants will receive either the C. difficile vaccine or a saline placebo, both given as shots into the upper arm muscle. The study duration varies based on the occurrence of diarrhea events related to C. difficile infection, lasting up to about three and a half years. The study may end earlier if sufficient data is collected or if the vaccine is found ineffective. Vaccination involves two doses, and participants will be closely monitored during and after vaccination. During the study, participants will have three planned clinic visits and three phone visits, followed by annual clinic visits until the study ends. If participants have three or more loose stools in 24 hours, they must save the next stool and contact the study site for infection assessment, which can occur in person or remotely. Researchers will track local and systemic reactions, adverse events, and the incidence of C. difficile infections as primary outcomes over the study period.
Actively Recruiting
Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.
Actively Recruiting
Researchers are evaluating pain levels in adults aged 35 and older who have high-grade partial or full thickness rotator cuff tears and are undergoing arthroscopic rotator cuff repair. The study compares standard post-surgical care with and without the addition of cold and compression therapy to understand how these treatments affect pain over time. The trial is randomized without masking and is sponsored by Ochsner Health System. Participants will be assigned to one of two groups. One group will receive standard therapy after surgery, including 28 hydrocodoneAPAP 7.5 mg pills with an option for a refill, plus cold therapy using ice bags or gel packs. The other group will receive the same pain medication along with a cold and compression therapy device provided by the sponsor. Treatment and monitoring will continue regularly from before surgery through six months after surgery. During the study, participants will have their pain recorded using the PROMIS Pain NRS subscale before surgery, daily for 14 days after surgery, weekly for three months, and again at six months post-surgery. Researchers will track pain scores as the primary outcome and monitor participants recovery and adherence to therapy. The study involves outpatient physical therapy for rehabilitation and requires participants to speak English and attend follow-up visits over the six-month period.
Actively Recruiting
This research aims to evaluate the effectiveness of a multi-level weight loss intervention called LA-CEAL CONNECT in adults living with obesity in Louisiana. The study will compare this intervention with enhanced usual care to determine if it leads to greater weight loss at 6 months and sustained weight loss at 12 months. It also aims to assess improvements in waist size, diet quality, physical activity, quality of life, and blood pressure, as well as the feasibility of implementing the program in community settings. Participants in the study will be randomly assigned to either the LA-CEAL CONNECT intervention or enhanced usual care. Those in the intervention group will receive culturally tailored educational materials, health coaching from community health workers over 6 months, tools for self-monitoring weight and physical activity using digital devices like a Fitbit and digital scale, and group meetings to connect with community health resources. Both groups will receive educational materials and their healthcare providers will get training and toolkits to support obesity management. During the study, participants will visit clinic sites at the start, 6 months, and 12 months to have clinical measurements and surveys collected. Researchers will monitor weight change as the main outcome at 6 months, along with changes in waist circumference, blood pressure, diet, physical activity, and quality of life. The study will last up to 12 months, with ongoing support and tracking of health behaviors through coaching and digital monitoring devices.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ravulizumab compared to placebo in adult patients at high risk of delayed graft function DGF following deceased donor kidney transplantation. The study aims to show whether ravulizumab can reduce the severity of DGF, specifically by shortening the time patients need dialysis after transplant. This phase 3, randomized, double-blind trial focuses on patients with dialysis-dependent end-stage kidney disease receiving kidneys from specific donor types. Participants will be randomly assigned to one of two groups one receiving intravenous infusions of ravulizumab, and the other receiving placebo infusions. The treatment is given intravenously, and participants receive either the study drug or placebo throughout the study. The trial compares these groups to assess the impact on DGF. The study is conducted across multiple centers and follows participants through 90 days after transplantation to measure outcomes. Throughout the study, participants will undergo regular assessments to monitor their kidney function and dialysis needs. Researchers will measure the time until participants no longer require dialysis, the number of dialysis sessions needed, the incidence of DGF within 7 days post-transplant, and kidney function as measured by eGFR. Safety and efficacy data are collected during the post-transplant period, with primary outcome measurements taken through 90 days after transplant. The total participation period extends until the studys completion in 2028.
Actively Recruiting
This research aims to collect real-world information about the treatment of lesions in the peripheral vasculature, focusing on patients who may not have been included in previous Peripheral Vascular Disease PVD studies. It evaluates the use of commercially available drug-eluting devices made by Boston Scientific Corporation to better understand their application and health economic impact globally. Participants in this registry receive treatment with Boston Scientific drug-eluting devices such as the Ranger14 Paclitaxel-Coated PTA Balloon Catheter and the ELUVIA14 Drug-Eluting Vascular Stent System. The study is observational and includes patients from multiple countries, with follow-up lasting up to 2 years in most countries and up to 5 years in China. Some participants at select sites will also complete additional assessments like quality of life questionnaires, six-minute walk tests, and healthcare utilization data collection. Throughout the study, participants undergo assessments based on standard care procedures. Researchers will monitor major adverse events and lesion patency at 12 months. Data collected includes health economics and patient outcomes to support the safe use of these devices. The total study duration extends up to 5 years depending on location, with scheduled follow-ups to gather ongoing information about treatment effects and patient health.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the real-world impact, including safety and test accuracy, of the Galleri4 multi-cancer early detection blood test in Medicare beneficiaries aged 50 years and older. This multi-center prospective cohort study aims to represent the Medicare population and compares usual care with and without the addition of the Galleri test. The study focuses on screening for cancer and assessing how the test affects cancer diagnosis and management over time. Participants are grouped into two arms one receiving the Galleri test alongside usual care, and a second group receiving usual care alone without the Galleri test. The Galleri test involves blood collection and multi-cancer early detection testing with results returned to participants. The study is non-randomized and runs parallel for both groups, observing outcomes over up to three years. During the study, participants are monitored for the incidence of late-stage stage IV cancers. Researchers also track safety by counting invasive procedures prompted by test results, adherence to recommended cancer screenings, and healthcare resources used for cancer diagnostics. The total study duration includes up to three years of follow-up to observe outcomes, with no masking or blinding involved.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
Actively Recruiting
Researchers are evaluating CARTISTEM, a new treatment made from stem cells derived from donated umbilical cord blood combined with a gel, to determine if it is safer and more effective than a standard surgical procedure called debridement for people with knee cartilage damage and osteoarthritis. This Phase 3 trial aims to show if CARTISTEM can reduce knee pain and improve function better than debridement two years after treatment. The study also investigates whether CARTISTEM may slow osteoarthritis progression using MRI scans. Participants will be divided into two groups one will receive CARTISTEM combined with debridement surgery, where the stem cell gel is placed into the damaged knee area after bone stimulation. The other group will undergo debridement surgery alone, which removes damaged cartilage and smooths the knee tissue. CARTISTEM involves mixing stem cells and a gel before placing it in the knee during surgery. Both groups will be monitored over two years. During the study, participants will have assessments of knee pain using the Visual Analog Scale and knee function using the WOMAC index from enrollment through 24 months. MRI scans will measure cartilage repair and osteoarthritis progression. Participants must follow rehabilitation requirements and limit other knee treatments during the trial. The study includes randomization and double-blinding to compare outcomes fairly while monitoring safety and effectiveness over time.
1-10 of 13
1